Sara Gandini

European Institute of Oncology (IEO) IRCCS

via Adamello 16

Milano, 20139

Italy

SCHOLARLY PAPERS

3

DOWNLOADS

263

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Predictors of Poor Seroconversion and Adverse Events to SARS-CoV-2 mRNA BNT162b2 Vaccine in Cancer Patients on Active Treatment

Number of pages: 24 Posted: 09 Aug 2021
Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Università degli Studi di Genova, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, Ente Ospedaliero Ospedali Galliera, European Institute of Oncology (IEO) IRCCS, Ente Ospedaliero Ospedali Galliera, European Institute of Oncology (IEO) IRCCS and Ente Ospedaliero Ospedali Galliera
Downloads 162 (376,749)

Abstract:

Loading...

SARS-CoV-2 vaccine, antibody responses to the bnt162b2 vaccine, SARS-CoV-2 vaccine adverse effects, cancer chemotherapy, cancer immunotherapy, cancer hormone therapy, cancer immunotherapy, cancer biological treatment.

2.

Estimating SARS-CoV-2 Circulation in the School Setting: A Systematic Review and Meta-Analysis

Number of pages: 33 Posted: 19 Jul 2021
European Institute of Oncology (IEO) IRCCS, European Institute of Oncology (IEO) IRCCS, European Institute of Oncology (IEO) IRCCS, INAF - Osservatorio Astronomico Aspromonte, University of Helsinki, European Institute of Oncology (IEO) IRCCS and European Institute of Oncology (IEO) IRCCS
Downloads 82 (618,692)

Abstract:

Loading...

3.

Effect of Age on Safety and Efficacy of Novel Cancer Drugs Investigated in Early-Phase Clinical Trials

Number of pages: 24 Posted: 17 May 2024
Cornell University - Weill Cornell Medicine, European Institute of Oncology (IEO) IRCCS, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Harvard University - Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, European Institute of Oncology (IEO) IRCCS, Harvard University - Dana-Farber Cancer Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Cornell University - Weill Cornell Medicine, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and European Institute of Oncology (IEO) IRCCS - Division of New Drugs and Early Drug Development for Innovative Therapies
Downloads 19 (1,081,118)

Abstract:

Loading...

Cancer, solid tumors, age, elderly, phase I, early-phase clinical trial, new drugs, adverse events, Survival, outcome